title: [Reversal effect of gambogic acid on multidrug resistance of K562/A02 cell line].
abstract: This study was purposed to investigate the reversal effect of gambogic acid (GA) on multidrug resistance of K562/A02 cells and its mechanism. The IC(50) (half maximal inhibitory concentration) of adriamycin (ADM) was evaluated by MTT. Cell apoptosis was detected by flow cytometry. Morphological changes of K562/A02 cells were observed by fluorescent microscopy with DAPI staining. The expressions of Survivin and P-gp were determined by Western blot. The results showed that the IC(50) of ADM on K562 and K562/A02 cell proliferation were (1.42 ± 0.07) µg/ml and (28.42 ± 1.40) µg/ml respectively. GA ≤ 0.0625 µmol/L had no inhibitory effect on proliferation of K562 and K562/A02. 0.0625 µmol/L GA could enhance the sensitivity of K562/A02 cells to ADM (P < 0.05) and the reversal multiples was 1.53. The apoptotic rate was raised after treating with ADM combined with 0.0625 µmol/L GA for 48 h (P < 0.05). Morphological differences were typical and obvious between cells of control and treated groups under fluorescence microscopy using DAPI staining. After treating K562/A02 cells with ADM combined with 0.0625 µmol/L GA for 48 h, the expressions of Survivin and P-gp were down-regulated at protein levels. It is concluded that GA can enhance the sensitivity of K562/A02 cells to ADM, which may be related to increasing cell apoptosis and down-regulating expressions of Survivin and P-gp.
authors.affiliation: Department of Hematology and Oncology, Southeast University Clinical Medical College, Nanjing, China.
authors.forename: Liang
authors.initials: L
authors.lastname: Tian
authors.forename: Juan
authors.initials: J
authors.lastname: Liu
authors.forename: Bao-An
authors.initials: BA
authors.lastname: Chen
authors.forename: Jian
authors.initials: J
authors.lastname: Cheng
authors.forename: Jia-Hua
authors.initials: JH
authors.lastname: Ding
authors.forename: Shuai
authors.initials: S
authors.lastname: Wang
authors.forename: Guo-Hua
authors.initials: GH
authors.lastname: Xia
authors.forename: Feng
authors.initials: F
authors.lastname: Gao
authors.forename: Ze-Ye
authors.initials: ZY
authors.lastname: Shao
authors.forename: Hai-Jun
authors.initials: HJ
authors.lastname: Zhang
authors.forename: Qing-Long
authors.initials: QL
authors.lastname: Guo
authors.forename: Hai-Wei
authors.initials: HW
authors.lastname: Zhang
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.forename: Yan-Yan
authors.initials: YY
authors.lastname: Ren
authors.forename: Xiao-Hui
authors.initials: XH
authors.lastname: Cai
authors.forename: Ran
authors.initials: R
authors.lastname: Liu
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D004317:Doxorubicin / Q000494:pharmacology; D018432:Drug Resistance, Multiple / Q000187:drug effects*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism; D020014:K562 Cells; D013373:Substance P / Q000378:metabolism; D000077022:Survivin; D044004:Xanthones / Q000494:pharmacology*
chemical_list: C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin; D044004:Xanthones; D013373:Substance P; D004317:Doxorubicin; C052659:gambogic acid